Clinical trial
A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
NCT01473524 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- December 17, 2018
- Enrollment
- 217 (actual)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.
primary biliary cirrhosis